Advances in JDM: biomarker and MRI sensitivity, outcomes and steroid management in a Dutch national prospective cohort
Authors' conclusion
This study demonstrates the superior diagnostic sensitivity of Galectin-9 and CXCL10 over CK, the high sensitivity of MRI and the frequent occurrence of refractory disease and flares despite treatment.
Study context
- Population
- JDM patients diagnosed 2007–2024 in the study-coordinating centre and 2015–2024 in five other Dutch tertiary referral hospitals65% female
- Participants
- 83 patients
- Outcome
- Characteristics and outcomes of the Dutch JDM population
Methodological detailsnational, multicentre
- National
- Multicentre
Main finding
As reported in the abstract
Characteristics and outcomes
- Median age at diagnosis (IQR 4-9), years
- 6.0
- Median follow-up (IQR 1.4-5.8), years
- 3.2
- Proximal muscle weakness at diagnosis
- 94.9%
- Gottron's papules/sign at diagnosis
- 79.7%
- CK abnormal
- 73.1%
- Galectin-9 elevated at diagnosis
- 98.3%
- CXCL10 elevated at diagnosis
- 93.3%
- Muscle oedema on whole-body MRI (30/33)
- 90.9%
- Corticosteroids tapered to 0.2 mg/kg at 6 months
- 41.5%
- ≥1 flare (27 patients)
- 32.5%
- Refractory disease course (24 patients)
- 28.9%
- Calcinosis (12 patients)
- 14.5%
- Clinically inactive disease without medication at last follow-up
- 28.9%
- Deaths
- 0
Observational data: associations, not effects.
Original publication
Advances in JDM: biomarker and MRI sensitivity, outcomes and steroid management in a Dutch national prospective cohort. Rheumatology (Oxford). Published 18 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →